{
    "Trade/Device Name(s)": [
        "SmartAdjust\u2122 technology"
    ],
    "Submitter Information": "Insulet Corporation",
    "510(k) Number": "K232741",
    "Predicate Device Reference 510(k) Number(s)": [
        "K220394"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QJI"
    ],
    "Summary Letter Date": "May 29, 2024",
    "Summary Letter Received Date": "September 7, 2023",
    "Submission Date": "September 1, 2023",
    "Regulation Number(s)": [
        "21 CFR 862.1356"
    ],
    "Regulation Name(s)": [
        "Interoperable Automated Glycemic Controller"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine"
    ],
    "Analyte(s)": [
        "Glucose",
        "Insulin"
    ],
    "Specimen Type(s)": [],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Omnipod 5 ACE Pump",
        "OP5 Pod",
        "OP5 Controller",
        "Compatible integrated continuous glucose monitors (iCGM)",
        "SmartBolus Calculator"
    ],
    "Method(s)/Technology(ies)": [
        "Algorithmic software",
        "Automated insulin delivery"
    ],
    "Methodologies": [
        "Automated glycemic control"
    ],
    "Submission Type(s)": [
        "Software",
        "System",
        "Accessory"
    ],
    "Document Summary": "FDA 510(k) summary for SmartAdjust\u2122 technology software enabling automated insulin delivery in hybrid closed-loop Omnipod 5 system for glycemic control.",
    "Indications for Use Summary": "For management of type 1 diabetes mellitus in persons 2 years and older, SmartAdjust\u2122 technology works with compatible iCGM and ACE pumps to automatically adjust insulin delivery based on current and predicted glucose values.",
    "fda_folder": "Clinical Chemistry"
}